36,323 Shares in Organon & Co. (NYSE:OGN) Acquired by Kingsview Wealth Management LLC

Kingsview Wealth Management LLC bought a new stake in shares of Organon & Co. (NYSE:OGN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 36,323 shares of the company's stock, valued at approximately $542,000.

A number of other hedge funds have also modified their holdings of OGN. Pacer Advisors Inc. increased its holdings in shares of Organon & Co. by 94,482.1% in the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company's stock valued at $166,391,000 after purchasing an additional 11,140,388 shares during the period. Weiss Asset Management LP acquired a new position in shares of Organon & Co. in the third quarter valued at about $32,966,000. Jacobs Levy Equity Management Inc. increased its holdings in shares of Organon & Co. by 303.8% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,242,135 shares of the company's stock valued at $23,762,000 after purchasing an additional 934,505 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Organon & Co. by 35.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company's stock worth $63,570,000 after buying an additional 875,128 shares during the last quarter. Finally, Philip James Wealth Mangement LLC purchased a new stake in shares of Organon & Co. in the third quarter worth about $15,386,000. 77.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

OGN has been the topic of a number of recent research reports. TD Cowen upgraded Organon & Co. to a "hold" rating in a research note on Wednesday, January 15th. Barclays lowered their target price on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a research note on Friday. Finally, Morgan Stanley lowered their price target on Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a research report on Friday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $20.80.

Organon & Co. Price Performance

OGN stock traded down $1.03 during mid-day trading on Friday, reaching $15.30. 4,424,393 shares of the company's stock were exchanged, compared to its average volume of 2,305,809. The company has a market cap of $3.94 billion, a price-to-earnings ratio of 3.03, a price-to-earnings-growth ratio of 0.83 and a beta of 0.76. The stock's 50 day moving average is $15.35 and its 200 day moving average is $17.42. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. Organon & Co. has a 12-month low of $13.87 and a 12-month high of $23.10.

Organon & Co. (NYSE:OGN - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). The firm had revenue of $1.59 billion during the quarter, compared to analysts' expectations of $1.57 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. On average, research analysts expect that Organon & Co. will post 3.82 EPS for the current year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 13th. Stockholders of record on Monday, February 24th will be given a $0.28 dividend. The ex-dividend date is Monday, February 24th. This represents a $1.12 annualized dividend and a dividend yield of 7.32%. Organon & Co.'s dividend payout ratio (DPR) is presently 22.22%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.